On October 18, 2024, Anutthara Bharadwaj, President of Atlassian Corp (TEAM, Financial), sold 760 shares of the company at a price of $188.79 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 228,996 shares of Atlassian Corp.
Atlassian Corp (TEAM, Financial) specializes in software development and collaboration tools, including its flagship products Jira and Confluence. These tools are widely used by teams to manage software development and facilitate team collaboration.
Over the past year, Anutthara Bharadwaj has sold a total of 42,953 shares and has not purchased any shares. This recent sale is part of a broader trend within Atlassian Corp, where there have been 565 insider sells and no insider buys over the past year.
Shares of Atlassian Corp were trading at $188.79 on the day of the sale, giving the company a market cap of approximately $50.14 billion. According to the GF Value, the intrinsic value of the stock is estimated at $257.56, suggesting that the stock is modestly undervalued with a price-to-GF-Value ratio of 0.73.
The GF Value is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and expected future business outcomes.
This sale by the insider might be of interest to current and potential investors, as it provides insight into the insider's perspective on the stock's valuation relative to its current market price.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
